HLA-mismatched allogeneic hematopoietic stem cell transplantation for standard-risk advanced hematological disease using low-dose alemtuzumab
- Conditions
- Standard-risk advanced hematological disease(leukemia and malignant lymphoma in remission, MDS, IMF, and SAA)
- Registration Number
- JPRN-UMIN000018283
- Lead Sponsor
- Division of Hematology, Saitama Medical Center, Jichi Medical University
- Brief Summary
The primary outcome measure of this study was DFS at 1 year, but it was below 50%, which was DFS at 1 year in the previous study using alemtuzumab. In this study, MDS with complex karyotype was included as a standard risk, and such patients relapsed. Risk stratification should be reconsidered. NRM was in an acceptable range. The improvements to decrease the RR are needed, such as the reduction of methotrexate dose based on the protocol which had used in high-risk patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Not provided
1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method